Leuprorelin - Tolmar

Alternative Names: Eligard; LA 2575; Leuprogel^®; SOT-375; SOU 375

Latest Information Update: 24 Mar 2018

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator QLT USA
Developer Tolmar
Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
Mechanism of Action Gonadotropin releasing hormone stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Prostate cancer
Phase III Precocious puberty
Discontinued Endometriosis

Most Recent Events

19 Feb 2018 TOLMAR Australia has been acquired by Mundipharma (China) Pharmaceutical
15 May 2017 Pooled pharmacokinetics data from four pivotal studies in Prostate cancer presented at the 112^th Annual American Urological Association Meeting in Boston (AUA-2017)
15 Mar 2016 Biomarkers information updated

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.